



ASX:RAD

RADIOPHARM THERANOSTICS

Newsletter | December 2021



OUR FIRST EDITION

Welcome message from the
Managing Director and
CEO Riccardo Canevari

PAGE 2

02

Message from
the CEO

04

From the Chair

06

What are
Radiopharmaceuticals?



RICCARDO CANEVARI
Chief Executive Officer
and Managing Director

Message from the CEO

Hello and welcome to the first edition of our newsletter. I've designed it to be informal yet factual and hopefully it will give you an insight into who we are and where we're going.

I can tell you without hesitation that it's going to be an interesting journey, but first, may I introduce myself. My name is Riccardo Canevari and I'm your new Managing Director and CEO. I am committed to bring value to your investment with us, and equally bring new and valuable therapeutic innovations to the fight, to defeat cancer in all its forms.

We may be new to the market and the ASX register, but we are long on experience and potential in a field of cancer research that has recently captured the imagination and intent of major pharmaceutical companies around the world.

Who are we?

We're a company harnessing the attributes of radiopharmaceuticals to diagnose and/or attack cancerous cells.

Diagnostically, we use low energy radioisotopes that allow physicians to see and evaluate disease in the body. Therapeutically we use high energy radioisotopes to treat and attack malignant, cancerous cells.

This is high tech innovation applied to pharmaceutical development!

How do we do it?

Therapeutically, we attach a radioisotope to a small molecule or antibody, and this agent subsequently binds to and delivers a very targeted radioactive dose that attacks the cell structure of the cancerous tumour.

Via this therapeutic application, it allows the delivery mechanism to be very selective as it precisely delivers an attack protocol that destroys the tumour.

We have four distinct platform technologies in our development basket including work with peptides, small molecules, and small and large monoclonal antibodies, that address approximately 75% of the causes of death from cancer. Within such, are five Phase 2 trials, and two Phase 1 trials with a total of 156 patients dosed to date. The clinical detail for these trials are available for you to review on our website.

We've set the bar high and we're working to a, 'first to market or best in class,' criteria. Our pipeline breadth and depth is unique! Our mantra is a development focus on radiopharmaceutical products for an unmet medical need in the fields of diagnostic and therapeutic applications.



We may be new to the market and the ASX register but we are long on experience and potential in a field of cancer research.

I'm also proud to tell you that we've put together a remarkable team of scientists hailing from august bodies such as The Imperial College in London, Memorial Sloan Kettering and The Technical University of Munich and with work experience within some of the world's most pre-eminent pharmaceutical companies.

I'll leave it to our chairman, Paul Hopper, to give you more background on their illustrious careers.

I'll sign off by saying I look forward to meeting you at our forthcoming events (current travel constraints aside) and extend the hope that you and yours are in good health and spirit.

With warmest regards,
Riccardo Canevari



What are Radiopharmaceuticals?


Diagnostic



Therapeutic



Radiopharmaceutical



Radiopharmaceuticals deliver radioactive isotopes to the tumour cells

- Diagnostic: Low energy radioisotopes which allow physicians to see and to measure disease within the body.
- Therapeutic: High energy particle emitters to treat malignant tumours, cancer, and other diseases.

The process involves attaching a radioactive isotope to a targeting agent such as a small molecule or antibody

- Peptides/mAbs specifically binds tumour cells.
- Peptides/mAbs are then loaded with Imaging Isotopes to **see** the tumour cells.
- Peptides/mAbs are loaded with Therapeutic Isotopes to **treat** tumour cells, being extremely selective to damage cancer cells DNA, while not damaging healthy tissues.



PAUL HOPPER
Chairman and Founder

From the Chair

May I open by saying well done and congratulations on becoming a shareholder with Radiopharm Theranostics Limited. I'm your chairman, Paul Hopper, and I extend an invitation to each and every one of you to reach out to me should you have any issues you wish to discuss in regard to your investment with our company.

Let's start from the top. You've read the introductory comments from our new Managing Director, Riccardo Canevari. Modest to a fault, his comments do not reflect the great attributes he brings to his role with us. We are fortunate indeed to have attracted a professional of his calibre to lead our team.

Let me tell you a bit about him. He comes to us from heavyweight pharmaceutical giant Novartis, where he was Chief Commercial Officer of their divisional company, Advanced Accelerator Applications (AAA), a company acquired by Novartis for US\$3.9 billion.

It is, by far, the leading radiopharma and nuclear medicine company in the world. Canevari's responsibilities included global commercial strategy in twenty countries throughout North America, Europe and Asia.

He was also senior VP and global head, breast cancer franchise for Novartis Oncology.

That's just his work ethic!

Canevari is also very involved as a father of 9y and 11y boys to support them in their school activities and extra school curricula (soccer and

music above all) through personal engagement during, usually fully busy, weekend schedule! He's also a proud husband to wife Marina, always feeling grateful to have her on his side in their multiple relocations around the world, settling in now, for the last five years, in New York greater area.

Joining him to bring Radiopharm Theranostics to the world, is our Chief Medical Officer, Professor David Mozley, a professor of nuclear medicine at Cornell University. Before his appointment with us, he was Chief of Nuclear Medicine and single site principal investigator for first-in-human pharma industry contracts from three large pharmaceutical companies.

Professor Mozley has participated in over 60 clinical trials at Eli Lilly, and over 100 at Merck, in novel radiopharma development. His expertise and commitment is also reflected in his third party advocacy of the field, as he has co-authored reports in more than 100 peer reviewed publications.

He is also a widely renowned, board-certified physician.



PROFESSOR DAVID MOZLEY
Chief Medical Officer



DR THOM TULIP
Chief Technology Officer

Jumping in the deep end of the talent pool with Canevari and Professor Mozley is our Chief Technology Officer, Dr. Thom Tulip. He has more than 25 years experience in the development and commercialisation of radiopharma and imaging agents.

When I say experience, Dr. Tulip is at the very pointy end of such. He's been a board member of The Academy of Molecular Imaging, and chairperson of the Institute for Molecular Technologies.

Dr. Tulip also held the chair of The Society of Nuclear Medicine's Corporate Advisory Board and served as director of The Council of Radionuclides and Radiopharmaceuticals.

Currently, he serves on the board of The Medical Imaging Technology Association (MITA).

I think you'll agree we have attracted professionals of the very highest calibre, and as their experience is brought to bear, you will see your company rapidly grow and prosper.

On the business side of the ledger, we have commercially attractive license arrangements backed by robust intellectual property and long life patents.

It's a new frontier in the oncology market, and there have been significant M&A deals globally exemplified by the Novartis'

acquisition of AAA for US\$3.9 billion, in tandem with their purchase of Endocyte for US\$2.1 billion.

Heady territory indeed.

On our own front, I am happy to tell you that we have raised AU\$20m in seed capital from institutions and sophisticated investors through the good auspices of brokers Bell Potter and Baker Young. These funds will be used as working capital, and to progress a highly prospective portfolio of radiopharmaceutical assets for diagnostic and therapeutic applications.

Again, welcome aboard and I hope you enjoy this brief hello from Riccardo and myself. It is designed to acknowledge your acuity in joining our register, and hopefully to stimulate you to seek more and further details on our protocols, all of which are chronicled on our website.

With warmest regards,

Paul Hopper

“

We have attracted professionals of the very highest calibre, and as their experience is brought to bear, you will see your company rapidly grow and prosper.

What are Radiopharmaceuticals?

They can be summed up in two distinct methods of operation; 'diagnostic,' in which we use low energy radiation to evaluate disease within the body and 'therapeutic', where we use high energy particle emitters, isotopes, that attack and destroy malignant tumours and targeted cancers.

The process is straightforward. We take one isotope and attach it to one of our proprietary peptides, or mAbs, and initiate either low energy imaging or high energy therapeutic attack on cancerous cells.

Our research to date indicates a very promising side effect. Our therapeutic isotopes seek out the DNA of cancerous cells but leave healthy tissue structure alone.

What is our involvement in the field?

We have four distinct, clinical platforms using peptides, small molecules, and antibodies. They are in the main spread over five Phase 2, and two Phase 1 clinical trials, with 156 patients participating to date. They are:

1. Pivalate

We are targeting brain, prostate, breast, and kidney cancers here in Phase 2 trials and we have seen superior imaging activity when compared to the traditional PET imaging standard. We will be moving to therapeutic evaluation in the first half of 2022.

Our inventor and remarkable partner is Professor Eric Aboagye of The Imperial College, London. We have negotiated a three year sponsored research agreement with the professor and his team, with a focus on therapeutic application.

2. Nano-mAbs

This is a unique technology based on single-domain camelid antibodies known as nano-mAbs. It is the exceptional work of Dr. Hong Ting, formerly of Oxford University, GE Healthcare and the Shanghai National Technology Centre. It also is a joint imaging and therapeutic platform, and our initial targets are HER2 breast cancer, PD-L1 for non small cell lung cancer, and Trop-2 for multiple tumours.

This is a therapeutic product, but also paired with a diagnostic platform, using the same antibody vector, but with a lower radiation radioisotope for imaging. Phase 1 trials are underway.

3. AvB6 Integrin

This is a highly promising clinical candidate for early detection of challenging cancers such as pancreatic, head and neck, and cervical. A Phase 1 trial is ongoing, and such is the respect for the research, that it featured in a peer review published by The European Journal of Nuclear Medicine in their September 2021 edition.

It is the genius of internationally acclaimed Integrin expert, Professor Johannes Notni, formerly of The University of Munich and now at The University of Essen. We have a three year sponsored research agreement, and strong collaboration in place with the professor and his team, with a primary aim to develop the therapeutic pathway solution.

4. PSA-mAb

This remarkable platform is at pre-clinical stage for research into a treatment for prostate cancer. It is a proprietary, humanised, monoclonal antibody that targets prostate cancer cells.

Preclinical data for both diagnostic and therapeutic platforms indicates a stable, humanised antibody without signs of degradation or aggregation.

Our research flows from the remarkable work of Professor David Ulmert, formerly with the Memorial Sloan Kettering cancer research centre and now leading his team at UCLA.

The above four platforms are brief by description due to the format of your newsletter, but fulsome detail on the science and the remarkable backgrounds of the scientists involved, are available on our website.

All four platforms have significant contractual commitments, and patent protection.

The field of Radiopharmaceuticals has arrived and has rapidly become a leading force in the fight against cancer. Your company is poised to make its mark within. We are fortunate indeed to have attracted the support and knowledge of the internationally acclaimed scientists who will influence and develop RAD as it presents its credentials to the world.

Team RAD

Here's a look at the remarkable team gathered to take your company to the world. It includes the founders of our four radiopharm technologies, senior management, board members and scientific advisors.

Team RAD recently met in London for a think tank revolving around the technologies and opportunities acquired by your company.

That's a very dry description of a gathering of minds that come from the very rarefied level of scientific achievement. We are both fortunate and proud to have attracted such

an illustrious group, to create and steer the development of RAD. Meeting shortly after the IPO, the interaction, as you can imagine, was wide reaching and covered discussion and planning of the company's clinical trials, manufacturing, business development, and human resource development.

As it was a first time meet for most of the team, it wasn't all work. We're reliably informed that like minds also have like attributes, and out-of-session meetings were convivial, as well as stimulating.

Front and centre in the pic is our chairman and driving force, Paul Hopper. Some would say bearing a remarkable resemblance to Gandalf, an association not that far removed from reality.





T +61 3 9824 5254
E info@radiopharmtheranostics.com
W radiopharmtheranostics.com

ASX:RAD